Genzyme Corp. (Nasdaq: GENZ) and Isis Pharmaceuticals Inc. (Nasdaq: ISIS) reported that a phase 3 clinical trial of their cholesterol treatment mipomersen met study goals but the stock prices fell. Genzyme lost 33 cents to $54.54 while Isis tumbled $1.58 to $9.46.